Cidara Therapeutics PE Ratio 2014-2022 | CDTX

Current and historical p/e ratio for Cidara Therapeutics (CDTX) from 2014 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Cidara Therapeutics PE ratio as of January 27, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Cidara Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-01-27 1.21 0.00
2022-09-30 0.63 $-0.55 0.00
2022-06-30 0.49 $-1.09 0.00
2022-03-31 0.83 $-0.72 0.00
2021-12-31 1.27 $-0.84 0.00
2021-09-30 2.24 $-1.07 0.00
2021-06-30 2.02 $-1.11 0.00
2021-03-31 2.66 $-1.74 0.00
2020-12-31 2.00 $-1.81 0.00
2020-09-30 2.85 $-1.74 0.00
2020-06-30 3.69 $-1.25 0.00
2020-03-31 2.48 $-1.29 0.00
2019-12-31 3.84 $-1.43 0.00
2019-09-30 2.00 $-1.45 0.00
2019-06-30 1.68 $-2.02 0.00
2019-03-31 2.65 $-2.66 0.00
2018-12-31 2.35 $-2.86 0.00
2018-09-30 4.40 $-3.11 0.00
2018-06-30 5.20 $-3.35 0.00
2018-03-31 4.00 $-3.21 0.00
2017-12-31 6.80 $-3.21 0.00
2017-09-30 8.10 $-3.40 0.00
2017-06-30 7.50 $-3.55 0.00
2017-03-31 7.80 $-3.41 0.00
2016-12-31 10.40 $-3.32 0.00
2016-09-30 11.45 $-3.16 0.00
2016-06-30 10.31 $-2.95 0.00
2016-03-31 12.70 $-2.69 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.087B $0.050B
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00